Although a study reported that selinexor increased PD-L1 and CTLA-4 transcript expression in mouse melanoma cells [58], we saw no evidence for increased PD-1 or CTLA-4 expression on human melanoma cells following treatment in a phase 2 clinical trial (NCT04768881) assessing selinexor in combination with pembrolizumab (unpublished observations). This evidence concerns the gene CD274 and melanoma.